Shopping Cart 0
Cart Subtotal
AED 0

Alzheimers Disease: Dynamic Market Forecast to 2026

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 31177

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 62353

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 93530
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Alzheimer's Disease: Dynamic Market Forecast to 2026

Summary

Alzheimer's Disease (AD) is a rapidly evolving field in which new developments are constantly influencing the market landscape.

The Dynamic Market Forecast is designed to help clients stay abreast of the latest news in the AD space, including regulatory, commercial, and clinical events as well as understand how all of these events will impact the projected market forecast.

Scope

Components of the slide deck include-

- Timeline of market-impacting events

- Key clinical trial landscape updates

- Detailed analysis of the most impactful events, including new primary research to gain Key Opinion Leader perspective

- Overview of updates to the forecast model based on anticipated future impact of events

- Forward-looking events calendar listing expected key updates to the AD competitive space through October2018-October 2021

Other events included in the analysis include-

- Regulatory filings

- Approval decisions

- Pricing changes

- Patent litigation

- Clinical trial data announcements

- Clinical trial failures

- Clinical trial timeline updates

Reasons to buy

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

- Develop business strategies by understanding the trends shaping and driving the global AD market.

- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global AD market in the future.

- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

READ MORE

Table Of Content

Scope

Table of Contents

1. Dynamic Market Forecast Overview 5

1.1 Related Reports 6

1.2 Upcoming Related Reports 7

2. Executive Summary 8

2.1 Key Updates to AD Market Dynamics 9

2.1 Key Events in Update 10-13

2.2 Clinical Trial Landscape Updates 14-15

2.3 Pipeline Landscape Updates 16

2.4 Market Insight on Key Events 17

3. Event 1: Approval and Launch of DMD Classes Will Revolutionize the Field of AD Therapeutics, Regardless of Their Cost 18

3.1 Key Updates to the Monoclonal Antibodies Market Dynamics 19

3.2 Biogen, Aducanumab 20-21

3.3 What Do Physicians Think? 22

3.4 Roche, Crenezumab 23

3.5 What Do Physicians Think? 24

3.6 Roche, Gantenerumab 25

3.7 What Do Physicians Think? 26

3.8 Competitive Landscape of Monoclonal Antibodies in AD 27

3.9 Summary/Trends 28

3.10 Sources 29

4. Event 2: Recent failures of large late-phase trials have cast doubts over AD drug developers 30

4.1 Key Updates to BACE Inhibitors and Combination with Vaccines Market Dynamics 31

4.2 BACE1 Discontinued in 2018 Based on Toxicity and Efficacy Concerns 32

4.3 Eisai, Elenbecestat 33

4.4 What Do Physicians Think? 34

4.5 Novartis, CNP520 35

4.6 What Do Physicians Think? 36

4.7 Novartis, CAD106 37

4.8 What Do Physicians Think? 38

4.9 Competitive Landscape of BACE Inhibitors and Combination with Vaccines in AD 39

4.10 Summary/Trends 40

4.11 Sources 41

5. Events Calendar 42

5.1 Key Events Expected to Occur in 2018-2021 43

6. Appendix 44

6.1 Methodology 45

6.2 Primary Research 46

6.3 About the Authors 47-49

6.4 About GlobalData 50

6.5 Contact Us 51

6.6 Disclaimer 52

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies


Companies

F. Hoffmann-La Roche

Biogen

Grifols

Novartis

Eisai

AZTherapies

Merck

AstraZeneca

Jannsen

Axovant

Otsuka

Intra-Cellular Therapies

TauRx Pharmaceuticals

Takeda

Archer Pharmaceuticals

Axsome Therapeutics

Avanir Pharmaceuticals

AB Science

Accera

Shire

Neurimmune

Amgen

Genentech

Lundbeck

MorphoSys

Eli Lilly

Alzheimer's Disease: Dynamic Market Forecast to 2026

Summary

Alzheimer's Disease (AD) is a rapidly evolving field in which new developments are constantly influencing the market landscape.

The Dynamic Market Forecast is designed to help clients stay abreast of the latest news in the AD space, including regulatory, commercial, and clinical events as well as understand how all of these events will impact the projected market forecast.

Scope

Components of the slide deck include-

- Timeline of market-impacting events

- Key clinical trial landscape updates

- Detailed analysis of the most impactful events, including new primary research to gain Key Opinion Leader perspective

- Overview of updates to the forecast model based on anticipated future impact of events

- Forward-looking events calendar listing expected key updates to the AD competitive space through October2018-October 2021

Other events included in the analysis include-

- Regulatory filings

- Approval decisions

- Pricing changes

- Patent litigation

- Clinical trial data announcements

- Clinical trial failures

- Clinical trial timeline updates

Reasons to buy

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

- Develop business strategies by understanding the trends shaping and driving the global AD market.

- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global AD market in the future.

- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

READ MORE

Scope

Table of Contents

1. Dynamic Market Forecast Overview 5

1.1 Related Reports 6

1.2 Upcoming Related Reports 7

2. Executive Summary 8

2.1 Key Updates to AD Market Dynamics 9

2.1 Key Events in Update 10-13

2.2 Clinical Trial Landscape Updates 14-15

2.3 Pipeline Landscape Updates 16

2.4 Market Insight on Key Events 17

3. Event 1: Approval and Launch of DMD Classes Will Revolutionize the Field of AD Therapeutics, Regardless of Their Cost 18

3.1 Key Updates to the Monoclonal Antibodies Market Dynamics 19

3.2 Biogen, Aducanumab 20-21

3.3 What Do Physicians Think? 22

3.4 Roche, Crenezumab 23

3.5 What Do Physicians Think? 24

3.6 Roche, Gantenerumab 25

3.7 What Do Physicians Think? 26

3.8 Competitive Landscape of Monoclonal Antibodies in AD 27

3.9 Summary/Trends 28

3.10 Sources 29

4. Event 2: Recent failures of large late-phase trials have cast doubts over AD drug developers 30

4.1 Key Updates to BACE Inhibitors and Combination with Vaccines Market Dynamics 31

4.2 BACE1 Discontinued in 2018 Based on Toxicity and Efficacy Concerns 32

4.3 Eisai, Elenbecestat 33

4.4 What Do Physicians Think? 34

4.5 Novartis, CNP520 35

4.6 What Do Physicians Think? 36

4.7 Novartis, CAD106 37

4.8 What Do Physicians Think? 38

4.9 Competitive Landscape of BACE Inhibitors and Combination with Vaccines in AD 39

4.10 Summary/Trends 40

4.11 Sources 41

5. Events Calendar 42

5.1 Key Events Expected to Occur in 2018-2021 43

6. Appendix 44

6.1 Methodology 45

6.2 Primary Research 46

6.3 About the Authors 47-49

6.4 About GlobalData 50

6.5 Contact Us 51

6.6 Disclaimer 52

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Companies

F. Hoffmann-La Roche

Biogen

Grifols

Novartis

Eisai

AZTherapies

Merck

AstraZeneca

Jannsen

Axovant

Otsuka

Intra-Cellular Therapies

TauRx Pharmaceuticals

Takeda

Archer Pharmaceuticals

Axsome Therapeutics

Avanir Pharmaceuticals

AB Science

Accera

Shire

Neurimmune

Amgen

Genentech

Lundbeck

MorphoSys

Eli Lilly